JP2025508841A - Gaa酵素補充療法の長期休止を伴うポンペ病を処置するための治療用アデノ随伴ウイルス - Google Patents

Gaa酵素補充療法の長期休止を伴うポンペ病を処置するための治療用アデノ随伴ウイルス Download PDF

Info

Publication number
JP2025508841A
JP2025508841A JP2024550218A JP2024550218A JP2025508841A JP 2025508841 A JP2025508841 A JP 2025508841A JP 2024550218 A JP2024550218 A JP 2024550218A JP 2024550218 A JP2024550218 A JP 2024550218A JP 2025508841 A JP2025508841 A JP 2025508841A
Authority
JP
Japan
Prior art keywords
gaa
administration
ert
aav
disclosed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024550218A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025508841A5 (cg-RX-API-DMAC7.html
Inventor
サム ホプキンス,
エドワード クリントン スミス,
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Duke University
Original Assignee
Duke University
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Duke University filed Critical Duke University
Publication of JP2025508841A publication Critical patent/JP2025508841A/ja
Publication of JP2025508841A5 publication Critical patent/JP2025508841A5/ja
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C12N15/86—Viral vectors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/43—Enzymes; Proenzymes; Derivatives thereof
    • A61K38/46—Hydrolases (3)
    • A61K38/47—Hydrolases (3) acting on glycosyl compounds (3.2), e.g. cellulases, lactases
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
    • C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
    • C12N9/2405—Glucanases
    • C12N9/2408—Glucanases acting on alpha -1,4-glucosidic bonds
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
    • C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
    • C12Y302/0102—Alpha-glucosidase (3.2.1.20)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/0083—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the administration regime
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024550218A 2022-02-25 2023-02-23 Gaa酵素補充療法の長期休止を伴うポンペ病を処置するための治療用アデノ随伴ウイルス Pending JP2025508841A (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US202263314093P 2022-02-25 2022-02-25
US63/314,093 2022-02-25
US202263319034P 2022-03-11 2022-03-11
US63/319,034 2022-03-11
US202263340972P 2022-05-12 2022-05-12
US63/340,972 2022-05-12
PCT/US2023/013713 WO2023164060A2 (en) 2022-02-25 2023-02-23 Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy

Publications (2)

Publication Number Publication Date
JP2025508841A true JP2025508841A (ja) 2025-04-10
JP2025508841A5 JP2025508841A5 (cg-RX-API-DMAC7.html) 2026-03-03

Family

ID=87766839

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024550218A Pending JP2025508841A (ja) 2022-02-25 2023-02-23 Gaa酵素補充療法の長期休止を伴うポンペ病を処置するための治療用アデノ随伴ウイルス

Country Status (8)

Country Link
US (1) US20250163457A1 (cg-RX-API-DMAC7.html)
EP (1) EP4482516A4 (cg-RX-API-DMAC7.html)
JP (1) JP2025508841A (cg-RX-API-DMAC7.html)
CN (1) CN119095612A (cg-RX-API-DMAC7.html)
AU (1) AU2023224856A1 (cg-RX-API-DMAC7.html)
CA (1) CA3252501A1 (cg-RX-API-DMAC7.html)
TW (1) TW202342109A (cg-RX-API-DMAC7.html)
WO (1) WO2023164060A2 (cg-RX-API-DMAC7.html)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2025053118A1 (ja) * 2023-09-04 2025-03-13 アステラス製薬株式会社 短縮型cmvプロモーター配列、及び/又は短縮型ポリアデニル化配列を含む組換えアデノ随伴ウイルス
WO2025235807A1 (en) * 2024-05-10 2025-11-13 Solid Biosciences, Inc. Compositions and methods to improve graft survival

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20020095135A1 (en) * 2000-06-19 2002-07-18 David Meeker Combination enzyme replacement, gene therapy and small molecule therapy for lysosomal storage diseases
US8679478B2 (en) * 2010-10-04 2014-03-25 Duke University Methods of lysosomal storage disease therapy
EP3293259A1 (en) * 2016-09-12 2018-03-14 Genethon Acid-alpha glucosidase variants and uses thereof
CA3106691A1 (en) * 2018-08-07 2020-02-13 Sangamo Therapeutics, Inc. Method for the treatment of mucopolysaccharidosis type ii
CN113423419A (zh) * 2019-01-04 2021-09-21 桑格摩生物治疗股份有限公司 用于治疗法布里病的方法和组合物
WO2021102107A1 (en) * 2019-11-19 2021-05-27 Asklepios Biopharmaceutical, Inc. Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
CA3254578A1 (en) * 2022-03-18 2023-09-21 AskBio Inc. Adeno-associated virus therapy involving an alpha-glucosidase (GAA) codon-optimized nucleic acid to treat Pompe disease, with signal peptide modifications

Also Published As

Publication number Publication date
TW202342109A (zh) 2023-11-01
CA3252501A1 (en) 2023-08-31
EP4482516A4 (en) 2026-03-25
US20250163457A1 (en) 2025-05-22
CN119095612A (zh) 2024-12-06
WO2023164060A2 (en) 2023-08-31
WO2023164060A3 (en) 2023-10-19
AU2023224856A1 (en) 2024-08-15
EP4482516A2 (en) 2025-01-01

Similar Documents

Publication Publication Date Title
JP2023503046A (ja) ポンペ病およびリソソーム障害を処置するための肝臓特異的プロモーターを含む治療用アデノ随伴ウイルス
US20200390888A1 (en) Novel aav mediated influenza vaccines
US12023386B2 (en) Composition for treatment of Crigler-Najjar syndrome
US12338451B2 (en) Compositions useful in treatment of metachromatic leukodystrophy
JP2018506261A (ja) 止血疾患を治療するための変異因子viiiのゲノム組込及び発現のための改良された発現カセット
WO2017106326A1 (en) Aav-anti pcsk9 antibody constructs and uses thereof
US20250163457A1 (en) Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy
US12247213B2 (en) Treatment of mucopolysaccharidosis IVA
Leon-Astudillo et al. Current avenues of gene therapy in Pompe disease
CN111601620A (zh) 用于21-羟化酶缺乏症的腺相关病毒基因疗法
TW202045728A (zh) 用於治療克拉培氏病之組成物
KR20250005569A (ko) 신호 펩타이드 변형을 갖는, 폼페병을 치료하기 위한 코돈 최적화된 알파-글루코시다제(gaa) 암호화 핵산을 사용하는 치료적 아데노-연관 바이러스
US20250161493A1 (en) Compositions and methods for in vivo nuclease-mediated treatment of ornithine transcarbamylase (otc) deficiency
HK40121378A (en) Therapeutic adeno-associated virus for treating pompe disease with long term cessation of gaa enzyme replacement therapy
KR20240099332A (ko) 파브리병의 치료를 위한 바이러스 벡터 작제물의 사용 방법
TW202526024A (zh) 用於治療龐貝症之具有異源訊號肽之利用編碼α-葡萄糖苷酶(GAA)之核酸之治療性腺相關病毒
HK40120720A (en) Therapeutic adeno-associated virus using codon optimized nucleic acid encoding alpha-glucosidase (gaa) for treating pompe disease, with signal peptide modifications
CA3048038C (en) Gene therapy for treating phenylketonuria
HK40087843A (en) Therapeutic adeno-associated virus comprising liver-specific promoters for treating pompe disease and lysosomal disorders
CN118202061A (zh) 使用病毒载体构建体治疗法布里病的方法
WO2025259575A9 (en) Methods and compositions for treatment of duchenne muscular dystrophy
CA3177924A1 (en) Compositions useful in treatment of krabbe disease

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20260220

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20260220